To help direct resources toward a potential new drug application resubmission for Barth syndrome therapy elamipretide, Stealth BioTherapeutics has laid off 30% of its workforce, the company announced May 29. The Needham, Massachusetts–based biotech did not specify how many employees it let go, but its LinkedIn People page lists 65 associated members, meaning the cuts may have affected around 28 staffers.